This study is designed to assess the safety and feasibility of injecting mesenchymal stem cells (MSCs) derived from a patient’s own fat tissue into the cerebrospinal fluid after a severe traumatic spinal cord injury. It uses autologous, culture-expanded adipose-derived MSCs (AD-MSCs) delivered intrathecally and remains experimental, with the goal of exploring its potential to support recovery in individuals with spinal cord injury.

This study evaluates the safety and tolerability of intrathecal allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in patients with traumatic spinal cord injury. It will also collect functional recovery outcomes after administration to generate preliminary evidence to inform a future Phase II efficacy trial.